To further expand their business, pharmaceutical giant Entod Pharmaceuticals is all set to launch its GLO division. This one-of-a-kind ophthalmic subspeciality division is focused on the treatment of the eye condition glaucoma, which is a leading cause of irreversible blindness in India. This comes after due consideration that awareness and timely treatment to deter the progress of glaucoma is the need of the hour.

Entod Pharmaceuticals has been at the forefront of working towards glaucoma education in the form of a nationwide public awareness campaign called the #TheGLOProject. The company has also tied up with the World Glaucoma Association and various national and regional glaucoma medical societies for this cause.

Speaking on this year’s achievements, Nikkhil K. Masurkar, CEO, Entod Pharmaceuticals said, “This year has been both challenging and exceptional for our business where we focussed on expanding our horizon beyond the convention. We have flourished in all the spheres that we set foot in. The latest milestone being the launch of our GLO Division is envisioned with the mission to ensure some real changes to the plight of glaucoma in our country.”

Anjula Masurkar, Clinical Director, Entod Pharmaceuticals said, “This move is bound to further strengthen ophthalmology medicine in India. Our GLO division will include some of the best quality anti-glaucoma medicines intended for promotion across the country and that too at competitor prices for patients. Over 95% of globally available anti-glaucoma molecules and therapies shall be covered through this division thereby giving access to crores of patients across the country. Furthermore, our research teams are currently engaged in investigating several new glaucoma therapeutic options that shall provide the latest treatment advances.”